GLP-1 drugs are entering a new chapter
Scientific Americansciam.com
This is what was read here when it was published. Scientific American no longer carries it in what it publishes now.
In this episode of Science Quickly, Scientific American’s associate health editor Lauren Young joins host Kendra Pierre-Louis to talk about how the story of GLP‑1 drugs such as Ozempic, Wegovy and Mounjaro is evolving. We trace GLP-1s’ origins as type 2 diabetes treatments, their rise as blockbuster weight‑loss medications and the ensuing complications—including the expanding market for compounded drugs. And we look at how the landscape has only grown more complex as researchers explore surprising potential uses for GLP‑1s, from addiction treatment to cardiovascular benefits, even…
